MindRank Pharma to Showcase AI-Driven Drug Discovery Platform and Clinical Pipeline at BIO-Europe 2025
MindRank
AI Drug Developer
From November 3 to 5, 2025, MindRank will participate inVienna, AustriaHosted European Biotechnology ConferenceBIO-Europe, and discuss cutting-edge trends and explore new opportunities for strategic cooperation with scientific leaders and industry pioneers in the global biopharmaceutical field.
The BIO-Europe conference is one of the premier platforms for companies in Europe's top innovation hubs to establish strategic partnerships with the global life sciences community, bringing together leading innovators and experts from the life sciences sector. Scholars, experts, enterprises, and forward-thinking investors from 70 countries around the world will gather to engage in in-depth discussions on the latest developments and future directions of the industry.
As a representative company in the AI pharmaceuticals field, MindRank is always committed to developing world-leading AI pharmaceutical platforms, accelerating the R&D of innovative drugs, and benefiting patients worldwide more quickly. Currently, at MindRankSelf-built Industrial-grade One-stop AI Pharmaceutical PlatformDriven by, MindRank's first self-developed byAI-Assisted Design of GLP-1RA Small MoleculesThe new drug MDR-001 has successfully completed Phase IIb clinical trials in May this year.About to Launch Phase III Trial. Phase IIb data show that subjects in the treatment groupAchieved a 10.3% weight loss within 24 weeksThe effect is remarkable, with excellent safety and tolerability. The clinical trial data for its once-daily dosing were also published in September this year, showing that subjects in the 12-week dosing group achieved an 8.9% weight loss. This achievement represents a key step in the application of AI technology in the field of innovative drug development, moving from concept to clinical validation, laying a solid foundation for the rapid advancement of the company's subsequent product pipeline.
MindRank sincerely invites global partners to visit and exchange ideas. If you wish to learn more about the company's innovative pipeline and business development, please feel free to contact us via the PartneringONE® collaboration system or email at bd@mindrank.ai. We look forward to expanding new collaborations and partnerships at BIO-Europe.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby making more diseases treatable and restoring health to more lives.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug R&D platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamics simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially influential startups."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai